 2 RB Annual Report 2013
after dividends, acquisitions  
& restructuring
Strong cash flow took  
net debt to
£2,096m
Strategic Report   Results Highlights
2014 Targets 
•	 	 Net	r evenue	gr owth	of	+4-5%	at	 
constant exchange rates, excluding  
RB Pharmaceuticals, including the 
immaterial residual impact of the  
Bristol-Myers Squibb (BMS) collaboration.
•	 	 Flat	to	moderate	operating	margin
3 
expansion, excluding RB Pharmaceuticals.
Medium-term KPIs (Key 
Performance Indicators)
•	 	 Health	and	hygiene	r evenues	to	incr ease	
as a percentage of core
4
 net revenue by 
1% per annum going forward.
•	 	 LAP AC
2
 and RUMEA
2
 combined to be 
equal in net revenue size to ENA
2
 by end 
of 2015.
•	 	 Achieve	200	bps	per	annum	of	net	
revenue growth on average above  
our market growth (excluding  
RB Pharmaceuticals).
•	 	 Achieve	moderate	operating	margin
3
 
expansion.
1   Excluding RB Pharmaceuticals at constant  
exchange rates.
2  Latin America, North Asia, South East Asia, and 
Australia and New Zealand (LAPAC), Russia and CIS, 
Middle East, North Africa, Turkey and sub-Saharan 
Africa (RUMEA), North America, Central Europe, 
Northern Europe, Southern Europe and Western 
Europe (ENA).
3   Adjusted to exclude the impact of exceptional 
items; and excluding RB Pharmaceuticals.
4   Core includes health, hygiene, home and  
portfolio brands.
RB Delivers Another 
Strong Year in 2013
68% 
volume share of the
US market
Suboxone Film maintained
Adjusted net income up +2% 
(+2% constant): 
269.8p
adjusted 
diluted 
earnings  
per share
These results give us 
confidence that we have 
the right business strategy, 
the right organisation, the 
right platforms and the right 
culture to deliver sustained 
growth and outperformance.
Operating 
margins
3
 up
exceeding target
+20 
bps 
Health & hygiene 
Powerbrands
Durex, Mucinex, Strepsils, 
Dettol, Lysol, Harpic & Finish 
led the growth
RUMEA
2
& LAPAC
2
Strong growth in
emerging market areas
Greater speed  
and scale
ENA
2
+4% 
total 
growth 
(at constant  
exchange rates)
Total net revenue
£10bn
Total 
growth
1 +7% 
